D G Page - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

D G Page

Showing results (71-80 of 74) with videos related to

Pageof 8

Sort By:

You have reached the last page of results.This site can display upto 74 results.

Leukemia|August 20, 2014

Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemiaAnna M Eiring, Brent D G Page, Ira L Kraft, et al.

Leukemia|May 4, 2017

Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemiaA M Eiring, B D G Page, I L Kraft, et al.

Nature Medicine|January 10, 2017

Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignanciesNikolas Herold, Sean G Rudd, Linda Ljungblad, et al.

Nature Chemical Biology|July 22, 2020

Development of a chemical probe against NUDT15Si Min Zhang, Matthieu Desroses, Anna Hagenkort, et al.

Pageof 8

Search research articles

Showing results (71-80 of 74) with videos related to

Sort By:

Pageof 8

You have reached the last page of results.This site can display upto 74 results.

Leukemia|August 20, 2014

Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemiaAnna M Eiring, Brent D G Page, Ira L Kraft, et al.

Leukemia|May 4, 2017

Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemiaA M Eiring, B D G Page, I L Kraft, et al.

Nature Medicine|January 10, 2017

Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignanciesNikolas Herold, Sean G Rudd, Linda Ljungblad, et al.

Nature Chemical Biology|July 22, 2020

Development of a chemical probe against NUDT15Si Min Zhang, Matthieu Desroses, Anna Hagenkort, et al.

Pageof 8